linjc16/ctgov huggingface dataset:
Exercise Controls Tumor Cell Growth Through AMPK Activation

Study Overview
=================
Brief Summary
-----------------
The study investigates the explanation for the positive relation found between exercise and breastcancer.

Official Title
-----------------
Running From Cancer

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Females age 18-30 BMI 18-25 Regular period Exclusion Criteria: Ingestions of any hormones Pregnancy Chronic inflammation Elite athletes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, Exercise, Myokines, AMPK
CUFF-assisted Colonoscopy vs Standard Colonoscopy

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to evaluate the interest of second-generation Endocuff Vision (ECV) to improve Adenoma detection rate and / or Polyp detection rate in routine colonoscopy. This is a prospective comparative cohort, on 1034 patients, 517 patients with ECV in prospective group and 517 without ECV in retrospective group

Official Title
-----------------
USE OF ENDOCUFF SECOND GENERATION IN THE COLIC POLYPS DETECTION: HISTORIC COHORTE PROSPECTIVE COMPARATIVE

Conditions
-----------------
Colonic Polyp, Colonoscopy

Intervention / Treatment
-----------------
* Diagnostic Test: cuff assisted colonoscopy(with cuff use of endocuff vision second generation)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient scheduled for total colonoscopic exploration, during the period study Patient over or equal to 18 years ASA 1, ASA 2, ASA 3 No participation in another clinical study Certificate of non opposition signed Exclusion Criteria: Patient under 18 years old ASA 4, ASA 5 Pregnant woman Patient with coagulation abnormalities preventing polypectomy: prothrombin level <50%, -Platelets <50000 / mm3, effective anti-coagulation in progress, clopidogrel in progress. Inflammatory bowel disease Known colonic stenosis Diverticulitis less than 6 weeks old Patient unable to give consent or protected by law Opposition expressed for inclusion in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| historical comparaison whithout cuff<br>517 patients included in 2017 without CUFF and 517 patients will be included in 2018 with CUFF for polyp detection | Diagnostic Test: cuff assisted colonoscopy(with cuff use of endocuff vision second generation)<br>* this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps<br>* Other names: standard colonoscopy ( without use of endocuff vision);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| detection of polyp or adenoma with cuff |  | during procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| POLYP DETECTION RATE |  | during procedure | 
| morbidity : perforation rate |  | 21 DAYS AFTER PROCEDURE | 
| CAECAL INTUBATION RATE |  | DURING PROCEDURE | 
| TIME TO REACH CAECUM | SEC | DURING PROCEDURE | 
| WITHDRAWAL TIME | SEC | DURING PROCEDURE |
Patient Satisfaction With Anesthesia Care

Study Overview
=================
Brief Summary
-----------------
The level of patient satisfaction is an important indicator of health care quality because it causes to reconsider the functioning of the hospital and go to the new regulations. Postoperative thought gives us important information for improving the quality of anesthesia care and health care quality. The investigators aimed to investigate the status of the anesthesia satisfaction in patients.

Detailed Description
-----------------
Patients will answer the questionnaire consisting of 15 questions

Official Title
-----------------
Satisfaction Rate of Patients Receiving Anesthesia in the First Half of 2015, in Erzincan

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Behavioral: satisfaction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing anesthesia between 18 - 65 years old to agree to participate in research undergo elective surgery Exclusion Criteria: be a psychiatric disorder cardiovascular surgery Emergency surgery patients with speech-hearing problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: satisfaction|anesthesia satisfaction rates|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anesthesia satisfaction rates |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patient Satisfaction, anesthesia Care
Monocentric Randomized Study, Assessing the Interests of the Determination of Vitamin D in Prison Population. (Vitamine D)

Study Overview
=================
Brief Summary
-----------------
The study will be proposed to man entering the prison of La Roche sur Yon. Participants will be randomized into two arms: one arm realize a dosage of vitamin D at the entrance and 6 months after the entry and the second arm will carry only a dosage six months after entry. the purpose of the study is to determine the interest of dosage of vitamin D in biological assessment of entry into prison house.

Official Title
-----------------
Monocentric Randomized Study, Assessing the Interests of the Determination of Vitamin D in Prison Population. (Vitamine D)

Conditions
-----------------
Male Prisoner

Intervention / Treatment
-----------------
* Other: Dosage Vitamine D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Incarcerated person Imprisoned in La Roche sur Yon Male Age > 18 year old Not opposed to participation in the study Exclusion Criteria: Intellectual deficit not to understand the study Taking osteoporosis treatment or any other affecting the metabolism of vitamin D Renal failure, liver failure Hypercalcemia Thyroid dysfunction, parathyroid diseases Duration of imprisonment less than the expected duration of the study. Incarcerated person who had received supplementation of vitamin D in the 6 months prior

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Dosage of vitamine D : inclusion and 6 month<br>Participant will have one dosage of vitamine D to entrance of prison and one dosage of vitamine D 6 month after entry | Other: Dosage Vitamine D<br> <br> |
| Other: Dosage of Vitamine D 6 month<br>Participant will have one dosage of vitamine D 6 month after entry to prison | Other: Dosage Vitamine D<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dosage of vitamin D |  | 6 month |
Amino Acid Usage Patterns in Daily Practice

Study Overview
=================
Brief Summary
-----------------
The present study aims to evaluate the patient profile including medical conditions who use a nutritional supplement along with a balanced and varied diet in Turkey.

Official Title
-----------------
An Observational Study to Evaluate Amino Acid Usage Patterns in Daily Practice

Conditions
-----------------
Wounds, Lean Body Mass

Intervention / Treatment
-----------------
* Other: Amino Acid Supplement Group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old. Consuming amino acid containing oral nutritional supplement before enrolment for malnutrition for hard-to-heal wounds or malnutrition due to primary disease. Followed by internal medicine or surgery departments. Exclusion Criteria: History of allergy or hypersensitive reaction to any ingredient in the amino acid containing oral nutritional supplement. History of any food allergy or intolerance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group Receiving Supplement<br>Amino acid supplement group | Other: Amino Acid Supplement Group<br>* Group receiving nutritional supplement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequencies of Medical Conditions | Diagnosis information | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intake of Amino Acid containing Nutrition Supplement |  | Baseline and Week 8 | 
| Anthropometrics | weight, BMI | Change from Baseline to Week 8 | 
| Laboratory Parameters | Pre-albumin/Albumin | Change from Baseline to Week 8 |
Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus

Study Overview
=================
Brief Summary
-----------------
To describe the prescribing patterns at Methodist Dallas Medical Center (MDMC) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of DOACs apixaban, dabigatran, and rivaroxaban in comparison to warfarin. With limited treatment guideline consensus, minimal evidence to support the use of DOACs for Left Atrial Appendage (LAA) thrombus and Left Ventricular Thrombus (LVT), and a lack of evidence for the use of DOACs in aortic thrombus, further research is warranted to determine the role of DOACs in the treatment of various mural thrombi in comparison to warfarin.

Detailed Description
-----------------
Retrospective chart review of MDMC patients from 4/1/2017 to 8/31/19 with newly diagnosed mural thrombus. 3.1. Study Methods Patients will be allocated into two groups: those who were prescribed DOACs upon discharge and those who were prescribed warfarin upon discharge Subgroup analyses will occur to evaluate the difference in efficacy and safety endpoints for patients into four categories including: those predisposed to mural thrombus by baseline risk factors (AFIB vs. ACS), location of the mural thrombus (atrial, ventricular, aortic), DOAC by agent (apixaban, rivaroxaban, dabigatran), and DOAC by scheduled dosing indication (AFIB vs. VTE).

Official Title
-----------------
Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus

Conditions
-----------------
Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years MHS patients with newly diagnosed mural thrombus from 4/1/2017 to 8/31/19 identified by International Classification of Diseases (ICD) codes: I23.6, I240, I513, I7409, I7411, I7419, I82210, I82229 Exclusion Criteria: Age <18 years Anticoagulant use at baseline (DOAC, LMWH, VKA) Active cancer Active bleeding Pregnancy Hospice or palliative care upon discharge Warfarin that did not receive adequate bridging from parenteral anticoagulation Non newly diagnosed mural thrombus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of the direct oral anti-coagulants | Readmission for recurrent stroke or thromboembolic event within 90 days of initial hospital discharge | from 4/1/2017 to 8/31/19 |
Surgery for Pancreatic Cancer With Oligo-Metastasis

Study Overview
=================
Brief Summary
-----------------
Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019). However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients. The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer

Official Title
-----------------
Surgery/Destruction for Stage IV Pancreatic Cancer With Oligo-Metastatic Disease

Conditions
-----------------
Pancreatic Cancer, Pancreatic Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Patients who had resection or destruction of one or more synchronous or metachronous metastases or local recurrence of pancreatic adenocarcinoma Details: synchronous lesions, metachrones can be included all distant lesions (hepatic, pulmonary) can be included documented lymph node involvement after analysis of the specimen (hepatic hilum, mesenteric root, retroperitoneal or inter-aortic-cellar) can be included patients with local recurrence who underwent surgical treatment Exclusion Criteria: - Patient who reject the study protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival at 3 years (percentage of patients alive). Overall survival (OS) (time from diagnosis until death, regardless of cause) | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression-free survival (percentage of patients without recurrence) at 3 years. Progression-free survival (PFS) (time from diagnosis to time of first radiological evidence of local, regional, or distant relapse, or death due to any cause) | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Surgery, Metastasis surgery, Survival, Multimodal treatment, Stage IV
Diffusion MRI in Appendicitis

Study Overview
=================
Brief Summary
-----------------
In this study, it was aimed to investigate the effect of diffusion-weighted magnetic resonance imaging on diagnosis and surgical decision in patients with suspected acute appendicitis. Investigators believe that Diffusion-weighted magnetic resonance imaging is a valuable method in the diagnosis of acute appendicitis and in making the decision of surgery.

Official Title
-----------------
Diffusion-Weighted Magnetic Resonance Imaging on Surgical Decision-Making in Acute Appendicitis

Conditions
-----------------
Acute Appendicitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with suspected acute appendicitis and scanned by diffusion weighted magnetic resonance imaging Exclusion Criteria: Patients evaluated by CT younger than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diffusion weighted magnetic resonance imaging | diffusion restriction | preoperative period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute appendicitis, Diffusion weighted magnetic resonance imaging, Diagnostic accuracy
Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation

Study Overview
=================
Brief Summary
-----------------
The study evaluates the use of half-normal saline as an irrigant for open-irrigated catheters during left ventricular outflow tract ventricular arrhythmias ablation. By increasing the efficacy of radiofrequency energy-mediated lesion formation, half-normal saline has the potential to reduce procedural times and improved acute and long-term outcomes.

Official Title
-----------------
Half-normal Saline vs Normal Saline for Irrigation of Open-irrigated Radiofrequency Catheters in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation

Conditions
-----------------
Ventricular Arrythmia

Intervention / Treatment
-----------------
* Drug: Half-normal saline
* Drug: Normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria male or female between 18 and 75 years of age at the time of enrollment undergoing first-time radiofrequency ablation for left ventricular outflow tract ventricular arrhythmias written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study Exclusion criteria ventricular arrhythmias originating from the right ventricular outflow tract according to the ventricular arrhythmia ECG morphology (i.e., precordial R wave transition at V3 or later) ventricular arrhythmias not originating from cardiac outflow tracts baseline hyponatremia (serum sodium level < 135 mEq/L) pregnant, breastfeeding, or unwilling to practice birth control during participation in the study presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Half-normal saline<br> | Drug: Half-normal saline<br>* Use of half-normal saline as an irrigant for open-irrigated ablation catheters<br>|
| Active Comparator: Normal saline<br> | Drug: Normal saline<br>* Use of normal saline as an irrigant for open-irrigated ablation catheters<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total radiofrequency ablation time, and total procedure time |  | intraprocedural | 
| acute success | elimination of the VAs, or <10 morphologically similar PVCs during a 15-minute waiting period | intraprocedural | 
| long-term success | elimination of the VAs, or a reduction of >75% of the PVC burden associated with marked improved in symptoms | 1 year |
Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry

Study Overview
=================
Brief Summary
-----------------
The NeuroBlate® System (NBS), is a minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. Since receiving FDA clearance in April 2013, the NBS has been used in nearly 300 procedures conducted at approximately 20 leading institutions across the United States. This post-market, multi-center retrospective study is designed to collect long-term follow-up data on patients who were treated previously with NBS.

Official Title
-----------------
Laser Ablation in Stereotactic Neurosurgery

Conditions
-----------------
Primary Brain Tumor

Intervention / Treatment
-----------------
* Procedure: NeuroBlate® System Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient was previously treated with NBS Patient is willing and able to provide informed consent and authorization for release of personal health information or IRB waiver is granted to collect study information without patient consent Exclusion Criteria: There are no exclusion criteria for this study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: NeuroBlate® System Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endpoint 1: Procedural Success Endpoint 2: Progression-Free Survival Endpoint 3: Overall Survival Endpoint 4: Karnofsky performance status | Retrospective data collection. | up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events |  | up to 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Progression, Quality of Life